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Psychometric Testing of the Heart Failure Somatic Awareness Scale
Abstract
Background: Self-management of heart failure relies on patients to assess their symptoms, but their ability to
do so is often difficult to determine. The 12-item self-report Heart Failure Somatic Awareness Scale (HFSAS)
was developed to measure awareness of and distress secondary to heart failure symptoms. The purpose of this
study was to test the psychometric properties of the HFSAS.
Methods and Results: Feasibility and discriminant validity of the HFSAS were tested in 49 patients admitted
for an exacerbation of heart failure. The HFSAS was acceptable to patients and discriminated between heart
failure symptoms and anxiety (r = 0.25, P = .08). When reliability and validity were tested in 201 patients with
acute heart failure, theta reliability was adequate (0.71). The HFSAS was low to moderately correlated with
general bodily awareness (r = 0.48). No difference was found based on gender, but younger patients had
higher mean and median HFSAS scores (more distress). The HFSAS was a significant predictor of symptom
duration prior to seeking care for heart failure; higher scores were associated with longer delay before seeking
care.
Conclusion: The HFSAS is reliable with content, discriminant, and construct validity. Evaluation of its
usefulness in teaching patients to monitor daily symptoms is needed.
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Abstract 
 
Psychometric Testing of the Heart Failure Somatic Awareness Scale 
Background: Self-management of heart failure relies on patients to assess their 
symptoms, but their ability to do so is often difficult to determine. The 12-item self-report 
Heart Failure Somatic Awareness Scale (HFSAS) was developed to measure awareness 
of and distress secondary to heart failure symptoms. The purpose of this study was to test 
the psychometric properties of the HFSAS.  
Methods and Results:  Feasibility and discriminant validity of the HFSAS were tested in 
49 patients admitted for an exacerbation of heart failure. The HFSAS was acceptable to 
patients and discriminated between HF symptoms and anxiety (r = 0.25, p 0.08). When 
reliability and validity were tested in 201 patients with acute heart failure, Theta 
reliability was adequate (0.71). The HFSAS was low to moderately correlated with 
general bodily awareness (r = 0.48). No difference was found based on gender but 
younger patients had higher mean and median HFSAS scores (more distress). The 
HFSAS was a significant predictor of symptom duration prior to seeking care for heart 
failure; higher scores were associated with longer delay before seeking care.   
Conclusion: The HFSAS is reliable with content, discriminant, and construct validity. 
Evaluation of its usefulness in teaching patients to monitor daily symptoms is needed. 
Key Words: Somatic awareness, instrument development, heart failure, symptoms 
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Psychometric Testing of the Heart Failure Somatic Awareness Scale 
Heart failure is a significant public health problem that affects 5 million 
Americans.
1
 As a chronic and progressive clinical syndrome, heart failure negatively 
affects a patient’s quality of life with unpleasant symptoms affecting well being, 
activities of daily living, and increases the risk of multiple hospitalizations for 
management of escalating symptoms. The ability of patients to monitor symptoms and 
maintain a complex regimen of multiple medications is essential for quality of life, 
avoidance of acute exacerbations and repeated hospital admissions. Nevertheless, self-
management of heart failure is difficult because of the non-specific symptom profile and 
the insidious nature of worsening symptoms. Thus, somatic awareness, defined as 
sensitivity to physical sensations and bodily activity secondary to physiological change, 
may improve patient ability to monitor symptoms. In this article, the development and 
testing of an instrument measuring the awareness or perception of heart failure symptoms 
is reported. 
Any personal description of symptoms is subjective by nature and therefore open 
to question.
2
 Aside from daily monitoring of body weight, however, the self-management 
of heart failure relies on self-assessment of symptoms. Such self-assessments are often 
what bring patients to the attention of health care providers. Therefore, self report of 
symptoms is extremely valuable for clinicians. 
Existing instruments measuring somatic awareness are general in nature and not 
cardiac or heart failure specific.
3, 4
 No measure of self-reported somatic awareness or 
perception of common heart failure symptoms is presently available. Those instruments 
that are heart failure specific are for the purpose of assessing the physical impact of 
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symptoms on activities of daily living,
5
 limit symptom assessment to fatigue and 
dyspnea,
6
 exclude perceived symptom severity,
7
 or measure patient response to 
symptoms in relation to effects on quality of life.
5, 6
 
Available instruments that address facets of general somatic awareness are not 
directed toward heart failure symptoms per se. Some are measures of general bodily 
awareness,
3
 emotion-related bodily responses,
8
 beliefs about bodily attentiveness,
4
 and 
bodily awareness specific to the symptom of palpitations.
9
 Other instruments assess 
distress associated with common physical symptoms
10
 or separate the components of the 
symptom experience into occurrence and distress level for symptoms that are not specific 
to heart disease.
11
 
Although none of these measures are heart failure specific, investigators have 
studied somatic or general bodily awareness in heart failure patients. Baas and 
colleagues
12
 used the Body Awareness Questionnaire
4
 to explore the relationship between 
body awareness and somatization among patients with heart failure or after heart 
transplant. No differences in physiologic body cues or specific symptoms were found 
related to age, gender, or treatment. Nor were there differences in bodily awareness with 
regard to negative mood states such as anxiety or depression. Body awareness as related 
to physiological cardiac parameters was not reported in the study. 
Despite emphasis on symptom monitoring in treatment guidelines for heart 
failure,
13
 available instruments remain limited to quality of life, number of symptoms and 
symptom impact. None are adequate measures of perception or awareness of heart failure 
signs and symptoms. As noted earlier, instruments measuring general bodily awareness 
are not sufficiently focused on cardiac related symptoms. As the constellation of 
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symptoms typical of heart failure can be both nonspecific (e.g., fatigue) and acute (e.g., 
paroxysmal nocturnal dyspnea), both are needed for any measure that would be useful in 
monitoring symptom distress, patterns, and duration whether symptoms are subtle or 
overt. Therefore, the development of a symptom specific instrument addressing both 
prodromal or early symptoms, as well as acute symptoms of a heart failure, was 
undertaken. 
Instrument Development 
The Heart Failure Somatic Awareness Scale (HFSAS) is a 12 item Likert-type 
scale to measure awareness and perceived severity of signs and symptoms specific to 
heart failure. Heart failure, primarily an illness of older adults, often incurs fatigue, so 
ease of administration and participant burden are important considerations. Furthermore, 
previous studies report both age and gender as factors affecting symptom reporting.
14-18
 
Consequently, evaluation for the presence of both age and gender bias was considered in 
the development and evaluation of this instrument. 
The HFSAS was limited to12 items to reflect the most common signs and 
symptoms of heart failure. A 4 point Likert-type scale was used to address these 
symptoms, and if present, to ascertain how much the patient was bothered by them at any 
point during the previous week.  An even number of Likert responses was used as the 
instrument was designed to assess an event, not force a choice. Patients determined a 
symptom as present or not, and then scored the perceived severity on a 0 to 3 scale as 
follows: 0 = Not at all; 1 = A little, slightly; 2 = A great deal, quite a bit; and 3 = 
Extremely, could not have been worse. Symptoms scored as 0 are symptoms not 
experienced by the patient. Scores range from 0 to 36 with higher scores reflecting higher 
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perceived somatic awareness and symptom distress. Pedal edema, one common sign, is 
addressed in 2 separate items to account for patients who change footwear to 
accommodate swelling. The HFSAS is written in lay terminology and has a second grade 
reading level. 
Content validity 
The symptom list was derived from a review of the literature and previous studies 
citing symptom lists for heart failure.
19-21
 Two nursing experts in the area of heart failure 
reviewed the symptom list to establish content validity. No recommendations to edit, add 
or delete items were suggested. 
Method 
Testing of the HFSAS was divided into 2 phases which are presented in 
sequential order for the reader. In phase1, feasibility factors including ease of 
administration, comprehensibility for the patients, and subject burden were evaluated. 
Phase 1 also included discriminant validity testing to address the relationship between the 
trait of anxiety and the HFSAS. The ability to discriminate between awareness of heart 
failure symptoms and symptoms secondary to anxiety was of concern for physiological 
and psychological reasons. Physiologically, sympathetic nervous system stimulation is a 
normal compensatory response to escalating heart failure symptoms resulting in an 
increased heart rate.
22
 Psychological anxiety can also produce sympathetic stimulation 
with similar symptoms, such as increased heart rate and sweating. Furthermore, patients 
in acute heart failure may experience difficulty breathing. Sympathetic symptoms of 
anxiety secondary to shortness of breath and emergent hospital admission are expected 
among patients with heart failure. Therefore, discriminate validity of the HFSAS was 
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evaluated as the ability to discriminate between psychological anxiety and symptom 
distress specific to heart failure. We hypothesized that the HFSAS would measure 
awareness of symptom distress and not anxiety. 
The Spielberger Trait Anxiety Inventory Form X-2
23
 was used to assess the 
correlation between proneness toward anxiety and somatic awareness as measured by the 
HFSAS. The Spielberger Trait Anxiety Inventory is a 20-item, 4 point Likert-type scale 
measuring a person’s general ongoing, typical level of anxiety. Scores range from 20 to 
80 points, with higher scores representing greater proneness to anxiety. Internal 
consistency and reliability of the scale is high (alpha coefficients of >0.89 for Trait 
Scale). Test-retest reliability correlations are reported between r =0.73 and r = 0.84.
23
  
Phase 2 analysis addressed construct and criterion validity and reliability testing. 
To determine construct validity, an exploratory factor analysis was performed by varimax 
rotation of the principal components. Consistent with the definition of criterion-related 
validity, which is the utility of an instrument to predict some behavior external to the 
instrument itself, 
24, 25
 the HFSAS was evaluated for its usefulness as a predictor of 
symptom duration. In patients with heart failure, symptom severity is related to symptom 
duration,
19
 with symptom duration, severity and novelty predicting care-seeking in 
community dwelling elders.
16
 Further construct analysis compared the HFSAS to a 
general measure of somatic awareness, the Modified Somatic Perception Questionnaire, 
and tested for differences between general or symptom specific bodily awareness in 
relation to symptom duration. 
Phase 2 analysis also included an exploration of variability in HFSAS scores to 
assess for potential bias. The HFSAS scores were divided into quintiles to examine for 
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relationships between the HFSAS scores and age, gender and duration of heart failure 
symptoms.  
Both phases testing the HFSAS were limited to community dwelling adult 
patients emergently hospitalized with a diagnosis of acute heart failure. Patients enrolled 
in Phase 1 were excluded from participating in Phase 2. Patients were enrolled if they 
made their own health care decisions and understood or read English. Patients with 
obvious cognitive impairment or unstable medical status were excluded. Cognitive status 
was evaluated by the medical and nursing staff caring for the patient. Patients who met 
the eligibility criteria and the Framingham Diagnostic criteria for heart failure
21
 were 
enrolled from acute care facilities in the northeast region of the United States. 
Institutional Review Board approval was secured from all appropriate authorities and 
informed written consent was obtained prior to participation. 
Phase 1 Procedure  
Phase 1 testing was completed in the emergency department phase by patients 
admitted to a community hospital for symptom management. Participants completed the 
HFSAS and the Spielberger Trait Anxiety Inventory. 
Phase 1 Sample 
A convenience sample of 49 patients admitted with acute heart failure was 
enrolled. The primarily Caucasian sample was 63% female with a mean age of 73 years.  
Phase 1 Results 
All patients completed the surveys without difficulty. Patients reported that the 
HFSAS items were clear as to content and easy to answer with respect to heart failure 
symptoms. The HFSAS had a mean score of 18.96 (SD 2.9) and a range of 13 to 25 out 
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of a possible score of 36. The Spielberger Trait Anxiety Inventory had a mean score of 47 
(S.D. 7.5) out of 80 and the Cronbach’s alpha coefficient was 0.92. There was no 
significant correlation between trait anxiety and the HFSAS (r = 0.25, p 0.08) supporting 
discriminant validity of the HFSAS and the hypothesis that the HFSAS measured 
awareness of symptom distress and not anxiety. 
Phase 2 Procedure 
Three sites were utilized in this phase, including one urban and one suburban 
tertiary care hospital and a community hospital. Patients were enrolled by the principal 
investigator or trained research assistants over a 15-month period, from October 2001 
until January 2003. At their request, the questionnaires were read to the vast majority of 
the patients. Visual difficulties secondary to aging are a concern to elderly patients when 
completing surveys.
26
 As patients with heart failure are generally older, the option to 
have the instruments read to the patient was incorporated into the procedure. Interviews 
were done during the hospital stay and completed as soon as possible after admission to 
minimize the confounding influence of patient recall; 87% of the patients were enrolled 
within 3 days of admission. Demographic and clinical data were collected by interview 
and review of the medical record.  
Phase 2 Sample 
The convenience sample consisted of 201 participants. The mean age of the 
sample was 70 years (± 12) and 39% were 75 years of age and older (Table 1). There 
were more males than females and the sample was predominately white. More than half 
of the patients reported previous admissions for acute heart failure. The majority of the 
patients had co-morbid illnesses typical of heart failure, including coronary artery 
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disease, hypertension, and diabetes. A minority (11%) participated in a heart failure clinic 
for management of their illness.  
Twenty-eight potential subjects declined to participate, including 14 females and 
14 males who, except for one Black male, were Caucasian. Reasons offered included 
time, the perception that the information was not important because they were elderly or 
lack of interest. The demographic characteristics of the final sample are typical of the 
geographic area. The subjects who declined participation were demographically similar 
to the final sample. 
Phase 2 Results 
In the phase 2 sample, the mean score on the HFSAS was 13.17 (S.D. 5.52) with a 
range of 0 to 29 out of a possible maximum score of 36. There were significant 
differences in HFSAS scores by age, with younger patients having higher median and 
mean scores (Table 2). Differences in median HFSAS scores based on gender did not 
reach statistical significance (p = 0.08). The greatest variability in HFSAS scores 
occurred in relation to duration of symptoms of acute heart failure such as acute dyspnea 
(Figure 1). As indicated by the left to right increase in box plot size in Figure 1, patients 
reporting the highest levels of distress secondary to the symptoms of heart failure had the 
most variability in terms of length of endurance of these symptoms prior to seeking care. 
Symptom duration did not differ significantly for patients who had been previously 
admitted for symptom management of heart failure and those admitted for the first time.  
Reliability Testing 
 The reliability of the HFSAS was assessed utilizing Theta reliability, an amplified 
Cronbach’s alpha useful for instruments with discrete items.
24
 Cronbach’s alpha, based 
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on interitem correlations, is most useful when correlations range between 0.30 and 0.40.
27
 
Only eight of these 66 interitem correlations fell into or above this range (0.31- 0.65) 
indicating that the items are largely discrete. Thus, theta reliability was appropriate. Theta 
reliability values are interpreted similar to Cronbach’s alpha. 
Initial reliability of the HFSAS, calculated after the first 50 participants of phase 2 
were enrolled, was 0.78. The theta was retested with the full final sample of 201 
participants, including the first 50 participants. Theta reliability was 0.71 in the final 
sample. No item would have increased the reliability coefficient if deleted, so all 12 items 
were retained for the final HFSAS. 
Validity Testing 
Construct validity 
To assess the constructs associated with the HFSAS, an exploratory factor 
analysis was conducted using a principle component analysis with varimax rotation.  
Results of the analysis produced a 4-factor solution using the criterion of an Eigenvalue 
greater than 1.0;
28
 58% of the variance in scores was explained (Table 3). The 4 HFSAS 
factors corresponded to the pathophysiology associated with heart failure. Factor I 
included the more acute heart failure symptoms of orthopnea, dyspnea, and paroxysmal 
nocturnal dyspnea. Factor II was comprised of the two items addressing symptoms 
related to peripheral edema. Factor III, with the exception of the symptom of cough, 
assessed items related to symptoms typically associated with myocardial infarction. 
Cough had the lowest factor loading (0.381) of all 12 symptoms. Factor IV represented 
the early symptoms of heart failure decompensation and included fatigue, weight gain, 
and dyspnea on exertion. Weight gain also loaded on Factor II, but was retained in Factor 
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IV where it had the highest loading. Similarly, dyspnea loaded on Factor IV and was 
retained in Factor I with the higher loading. 
The HFSAS was analyzed for convergent and divergent construct validity in 
comparison with general somatic awareness as measured by the Modified Somatic 
Perception Questionnaire. The HFSAS had a low to moderate correlation with general 
somatic awareness (Spearman ‘s rho r = 0.48), indicating that the instruments measure 
something in common, but not the same construct. 
Criterion-related validity  
The HFSAS was examined for its ability to predict duration of symptoms prior to 
care-seeking for acute heart failure. The HFSAS score was a significant predictor of 
symptom duration, with higher scores associated with increased time from symptom 
onset to arrival at the hospital. That is, in spite of increased somatic awareness, patients 
delayed longer. Further analysis revealed that the pattern of symptom onset was 
accountable for this counter intuitive result. Patients with a gradual symptom onset 
waited until their symptoms reached a severe level prior to seeking care. The HFSAS was 
also a significant predictor of duration of acute symptoms in the linear regression model 
after adjusting for demographic and clinical factors known to influence the symptom 
experience (Table 4).
19, 29-31
 The duration of acute symptoms increased approximately 
one hour for every one point increase in the HFSAS score. Similarly, an increase in the 
HFSAS score was associated with an increase in duration of dyspnea, acute dyspnea, and 
dyspnea on exertion. Acute dyspnea was defined as a sudden onset or increase over 
baseline levels of chronic dyspnea. Dyspnea on exertion was shortness of breath noticed 
only with activity. A subscale of the HFSAS measuring the acute symptoms as a group 
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(dyspnea, orthopnea, paroxysmal nocturnal dyspnea, and dyspnea on exertion) was 
predictive of an increase in acute dyspnea duration. The Modified Somatic Perception 
Questionnaire was not a significant predictor of symptom duration in the regression 
model, but HFSAS was predictive, after controlling for other factors such as age and 
pattern of symptom onset. Based on these analyses, the HFSAS was judged to have 
construct and criterion-related validity.   
Discussion 
Patients with heart failure are asked to monitor their symptoms on a daily basis to 
facilitate early interventions that may avert hospitalization. Availability of a reliable and 
valid measure of somatic awareness may be useful in assisting patients to become more 
aware of symptoms. In particular, attention to and care of the early symptoms of heart 
failure decompensation is important in averting unnecessary hospitalizations. This first 
test of the HFSAS is promising. The HFSAS was shown to be reliable with content, 
discriminate, and construct validity. No gender bias was evident in scores.  
The reliability of the HFSAS was adequate to support further testing, but it was 
lower than anticipated, which may reflect the limited number of items or the variable 
symptom profile among patients with heart failure. Borderline reliability could reflect the 
brevity of the instrument, which was intentional to minimize participant burden. In an 
effort to improve reliability, further development and testing of the HFSAS will address 
adding items that assess symptoms that are difficult to measure. Dyspnea on exertion is 
one such factor, since patients tend to decrease activity in order to accommodate 
symptoms.
32
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Somatic awareness, when measured with the symptom specific HFSAS, was a 
significant predictor of duration of symptoms, thus supporting validity of the instrument. 
The Modified Somatic Perception Questionnaire, a general somatic tool, was less 
effective in predicting symptom duration. An instrument such as the HFSAS may 
enhance the ability of patients and health care providers to monitor symptom acuity based 
on patient status at baseline.   
Interestingly, patients who had previously experienced an exacerbation of heart 
failure did not seek care any sooner than patients admitted for first time exacerbation of 
illness. One possible explanation is that previous experience with decompensation in 
heart failure does not provide sufficient knowledge for patients to avoid a hospital 
admission. These results contrast with those of Francque-Frontiero et al.
33
 who found that 
experience with heart failure predicted self-care ability. Another potential explanation for 
this difference in findings is the outcome variable. Francque-Frontiero et al. found that 
patients with more experience had better self-care, but they did not assess the adequacy 
of self-care to prevent hospitalization, as we did. Our results suggest that it may take 
more than first hand experience to teach patients how to avoid rehospitalization.  
The accuracy or validity of patient self reports is regularly questioned. Meek and 
colleagues,
2
 studying a small sample of stable patients with chronic obstructive 
pulmonary disease, reported accurate recall of the average intensity of symptom 
experiences for a 2 week period. After regression analysis, however, the authors 
concluded that patient recall of symptom intensity for the 2 previous weeks was 
influenced by current symptom intensity. That is, when current symptoms are mild, the 
severity of relatively recent symptoms may be down-rated. Therefore, it may be advisable 
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to have patients evaluate the number and intensity of symptoms currently being 
experienced, as well as those in the recent past. In a secondary analysis of heart failure 
patients in the SOLVD clinical trial,
34
 patient self report of physical status predicted 
hospitalization as well as or better than physiologic or clinician assessments. In a study of 
acute and prodromal symptoms in women with myocardial infarction, McSweeney 
reported accurate symptom recall based on acceptable test-retest scores 7 to 14 days 
later.
35
 
Although not always feasible, asking patients to rate symptoms may require 
validation from others.
36
 Additionally, it may be difficult for patients with chronic, 
omnipresent symptoms to objectively rate their degree of distress especially when it 
involves incremental change, which must be assessed in the context of daily life. For 
example, a patient may feel a symptom is severe, but rate the discomfort as less 
bothersome if able to continue with daily activities. Qualitative studies of persons with 
heart failure illustrate that patients learn to live with symptoms over time.
37, 38
 
The HFSAS was tested in patients hospitalized for acute decompensated heart 
failure. The reliability and validity of the HFSAS among patients with chronic stable 
heart failure has not yet been explored and test-retest reliability has not been established. 
Furthermore, the effect of reading to the patient needs to be determined. A lack of ethnic 
diversity in the sample is also a limitation to generalizability. 
Despite these limitations, the HFSAS may be useful in studies designed to 
improve symptom recognition and self-management. Using the HFSAS to establish 
baseline status may be clinically valuable in gauging the importance of the daily ebb and 
flow of symptoms. Fostering awareness of the early symptoms of decompensation may 
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avert repeated hospital admission for symptom management. The ultimate goal is to 
facilitate effective self-monitoring of the symptoms of heart failure in this growing 
population.  
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Table 1. Sociodemographic characteristics of the Phase 2 sample (n = 201). 
 Age (years) Mean 70 (SD ±12) 
 
Gender 
     Female 
n  and  % 
88 (44%) 
Marital Status 
     Married 
     Widowed 
     Divorced, separated, never married 
 
99 (49%) 
62 (31%) 
40 (20%) 
Race 
     White 
     Black 
     Hispanic 
 
191 (95%) 
8 (4%) 
2 (1%) 
Education 
     Less than 12 years 
     High School Diploma 
     Some college 
     Bachelors Degree 
     Graduate Degree 
 
58 (29%) 
69 (34%) 
45 (22%) 
15 (8%) 
14 (7%) 
Co-morbid Illness 
     Coronary Artery Disease 
     Hypertension 
     Diabetes 
 
142 (71%) 
144 (72%) 
106 (53%) 
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Table 2. Phase 2 HFSAS scores by quintile of age. 
 1 2 3 4 5 
AGE 37-60 61-70 71-75 76-80 81-97 
N in stratum 52 46 30 36 37 
      
Mean 15.4 13.6 12.2 10.9 12.5 
Standard Deviation  6.4 4.8 6.6 3.6 4.5 
*Median 15 13.5 12 10.5 12 
Minimum 0 0 0 4 3 
Maximum 29 25 28 20 23 
      
Kruskal-Wallis test  
 
*p-value = 0.002  
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Table 3. Factor Loadings in the Rotated Factor Matrix for the 12-item HFSAS (n = 201) 
 
Item 
 
Factor 1 Factor 2 Factor 3 Factor 4 
I could feel my heart beat get faster   .523  
I could not breathe if I lay down .819    
I felt pain in my chest   .644  
I had an upset stomach   .738  
I had a cough   .381  
I was tired    .627 
I could not catch my breath .619   .523 
My feet were swollen  .877   
I woke up at night because I could not 
breathe 
.732    
My shoes were tighter than usual  .874   
I gained 3 or more pounds in the past 
week 
 .472  .501 
I could not do my usual daily activities 
because I was short of breath 
   .709 
          
        Eigenvalue       2.86           1.75          1.25      1.08 
        Percentage of variance      23.8            14.5                10.4             9.0 
        Cumulative percent      23.8             38.4                48.8            57.8 
      _____________________________________________________________________ 
An underlined value indicates loading of an item on 2 factors.
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 Figure 1. Duration of acute symptoms in hours by quintile of the HFSAS score. 
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For example, in the HFSAS quintile of 19-29, the mean is 32.2 hours. 
 
*-----* indicate the median duration of acute symptoms. 
             
0 and * indicate the outliers in each quintile. 
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Table 4. Estimated change in duration of acute symptoms associated with HFSAS scores  
 
among subjects with acute symptoms  72 hours:  n = 171. 
   
                                                                            Beta                 SE                   p
   
Heart Failure Somatic Awareness 
 
.88 .25 .0007 
Controlling for
 
 
   
Previous heart failure experience 
 
.87 .26 .001 
Age (continuous) 
 
.80 .26 .002 
Age > 75 years (dichotomous) 
 
.84 .26 .001 
Living alone (dichotomous) 
 
.89 .26 .0006 
< High School (dichotomous) 
 
.82 .26 .002 
Insulin dependent (dichotomous) 
 
.90 .26 .0006 
Male gender (dichotomous) 
 
.91 .26 .0005 
  Sudden symptom onset(dichotomous) 
 
.78 .25 .002 
General Body Awareness (MSPQ) 
 
1.26 .30 <.0001 
 
Unstandardized Beta scores interpreted in hours 
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As a chronic illness, heart failure (HF) negatively affects quality of life with symptoms 
that limit activities of daily living and increase the risk of acute hospitalization.1, 2 Effective self-
care, with daily symptom monitoring and knowledgeable decision-making about symptoms 
when they occur, can help patients with HF maintain an acceptable quality of life and avoid 
repetitive hospitalizations. Symptom monitoring is particularly difficult because symptoms such 
as fatigue and cough are not specific to HF. Many patients with HF have comorbid conditions 
that can mask or mimic HF symptoms. Furthermore, symptoms vary from patient to patient, 
can increase insidiously over time, and are often misattributed to normal aging or a less 
threatening illness.3 Symptom monitoring difficulties arise when patients try to distinguish a 
progression in HF symptom severity (signaling an acute exacerbation) from that of a comorbid 
illness, normal age-related changes in physical health, or chronic baseline symptoms. 
Despite patient education on self-care, emergent hospital admission for acute symptom 
management remains common among patients with HF. Patients routinely report experiencing 
symptoms for a week or more before seeking care for an exacerbation.4-6 The reasons for this 
delay are multifactorial, but symptom characteristics, patterns of symptom onset, and failure to 
recognize symptoms are related to longer delay.3, 7-10 Clearly, better methods of teaching HF 
patients how to recognize and manage their symptoms are needed. The purpose of this study 
was to test the efficacy of a HF symptom training program, the HF Symptom Monitoring 
Awareness & Response Training (HF SMART), on patients’ ability to recognize and respond to 
changes in HF symptoms. The primary aim was to compare event-free survival at 90 days in 
participants randomized to the HF SMART intervention versus those receiving usual care.  
BACKGROUND AND SIGNIFICANCE 
*3) Blinded Manuscript (without author details)
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     Difficulties with symptom recognition have been reported by both newly diagnosed and 
patients relatively more experienced with HF.3 Horowitz and colleagues identified recognition, 
interpretation and response to symptoms as limitations to seeking timely medical intervention, 
with difficulty sensing an increase over baseline symptoms as particularly problematic.3 Patients 
sought care for the more acute symptoms of HF after early symptoms of HF decompensation 
were missed. Failure to see HF as a chronic illness that required daily monitoring and 
management also impeded effective self-care. If symptoms were not severe, they were not 
attended to.  
Patient education, a cornerstone of HF treatment, is directed at promoting self-care by 
focusing on adherence to therapy and monitoring of symptoms. Patients are instructed to 
monitor for signs and symptoms of volume overload (weight gain, edema, increasing dyspnea, 
and fatigue). Written materials describing the essential elements of self-care are usually 
provided to patients. Despite these efforts, readmission rates are over 30% 3 months11-13 after 
initial hospitalization and as high as 47% at 6 months.14, 15 Clearly, knowledge alone is 
insufficient to improve outcomes.  
Tested strategies designed to improve HF outcomes generally can be divided into two 
categories. One type is intense follow-up of patients by health care providers (e.g., frequent 
phone calls)13, 16-24 and the other aims to enhance patient self-care.11, 12, 25 Not surprisingly, 
intense follow-up by health care providers decreased HF admissions in recent meta-analyses.26-
28 However, trials of enhanced self-care activities were even more effective in decreasing HF-
related readmissions than those using intense follow-up strategies (RR 0.66 vs. RR 0.72-0.76). In 
other words, self-care interventions decreased admissions by 34% compared to 26% with 
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intense follow-up.29 It should be noted that the effect of self-care was implied in many of the 
studies, as it was not explicitly measured in all investigations included in the meta-analysis. 
Finally, increased intensity of the provider follow-up did not always yield better outcomes. For 
example, Shah et al23 reported a high readmission rate despite optimization of medications, 
frequent medical surveillance, and patient education for self-directed diuretic adjustment.   
Clinical trials of enhanced patient self-care interventions decreased readmission rates in 
three of the five studies specifically targeting self-care practices.11, 12, 25, 30, 31 The effective self-
care interventions included education11, 25, 30 with intermittent telephone follow-up.25, 30 One 
study that was not effective in decreasing readmissions tested a brief educational intervention 
that began during hospitalization with a follow-up home visit within 10 days after discharge.12 
Patients could call the study nurse between discharge and the home visit if problems occurred. 
Self-care abilities improved, however, readmission rates were not statistically different 
between the intervention and the control group (p=.06). The other study tested a tailored 
message based on patients’ perceived benefits and barriers to self-care.31 In the subjects 
receiving the tailored messages, barriers and benefits of medications, diet, and self-monitoring 
all improved over a one month period but readmission rates and quality of life did not differ 
between the intervention and control groups at one month. Although education was an 
emphasis of all these trials, the elements associated with improved self-care remain unclear, 
although confidence in the ability to perform self-care has been shown to be important to 
improving self-care.32, 33  
The optimal strategy for promoting HF self-care should be straightforward, 
standardized, and useful for a variety of health care providers in a variety of settings (hospital, 
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private practice, clinics). Interventions that could be easily incorporated into existing routines 
(e.g., discharge teaching) and subsequently reinforced by any health professional would be an 
important adjunct to current practice. The intervention tested in this pilot study was intended 
to fill this gap. 
Intervention  
The HF SMART intervention was developed from theory,34-40 published literature, and 
our preliminary studies on response to HF symptoms.5, 10 The HF SMART intervention, directed 
at symptom monitoring and response, is embedded in the Theory of HF Self-Care40 (Figure 1). In 
this theory, self-care is defined as a naturalistic decision making process comprised of self-care 
maintenance, self-care management, and self-care confidence.40 Respectively, these 
components of self-care are maintenance or adherence behaviors that prevent an acute 
exacerbation of HF (e.g., daily weighing), self-care management or the ability to recognize and 
respond to symptoms when they occur (e.g., take an extra diuretic for shortness of breath) and 
confidence in the ability to perform self-care.41 Confidence in self-care, not actually a part of 
the self-care decision-making process, has been shown to be an important influence on self-
care behaviors.32, 33  
The intervention consisted of provision of a weight scale and HF self-care booklet, a 6-
minute walk test, instruction on daily symptom graphing (tailored to participants), and a home 
visit to review the training. Excluding the home visit, the intervention takes 20 to 30 minutes to 
complete. HF SMART uses an interactive exercise to compare sensations of dyspnea and fatigue 
at rest and immediately after activity. Commonly patients are asymptomatic at rest so an 
important component of HF SMART was teaching patients to evaluate symptoms associated 
 5 
with activity. Participants also were instructed to evaluate symptoms as clusters as opposed to 
discrete entities. As the early symptoms of HF decompensation such as fatigue and weight gain 
are not specific to HF, assessing symptoms as clusters aids identification of symptoms as HF-
related or not.  
The intervention uses somatic awareness (How hard is it to breathe? Is my breathing the 
same, better or worse than yesterday?) and cognitive awareness techniques (Are my symptoms 
related to HF?). The manner in which techniques are integrated is designed for incorporation 
into the patient’s usual daily physical activity routine (e.g. bathing and dressing). Associating 
daily symptom monitoring with activities like hygiene and dressing serves a dual purpose. One, 
using a typical routine provides a schedule for the activity and two; hygiene activity helps to 
benchmark the level of dyspnea and fatigue day to day. The HF SMART protocol also prescribes 
a time and provides a context for repetitive self-monitoring of symptoms. A daily Symptom 
Graph was provided and reviewed to help patients track and graph symptoms (dyspnea, 
fatigue, weight, presence or absence of edema), and respond to symptoms (e.g. contact with 
health care providers). Directions on daily symptom monitoring including an example of a 
symptom graph with a change in symptom status were provided on a laminated card.  
Individual HF symptom profiles were determined using the HF Somatic Perception 
Scale,42 discussed further below, to account for potential variability in symptoms between 
patients. Dyspnea was a focus of the protocol because it was the most commonly reported 
symptom in our preliminary studies5, 43 and others examining delay in care-seeking for acute 
HF.4, 6 To mimic the sensation of dyspnea, the 6-minute walk test was used stimulate 
respiratory effort and link the change in somatic sensation associated with activity. Respiratory 
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effort and fatigue were rated at rest and immediately after the 6-minute walk test using a visual 
analogue scale.44 Ratings of dyspnea and fatigue with activity ranging from 0 (no symptoms) to 
10 (dyspnea or fatigue as bad as it can be) were then entered on the symptom graph. The 
Symptom Graph focused on fatigue and dyspnea because persistent fatigue and dyspnea on 
exertion at time of discharge have been reported in slightly more than 40% of patients 
hospitalized with acute HF.45 The Symptom Graph was altered for patients whose most 
frequent or bothersome symptoms were other than dyspnea and fatigue. Each Symptom Graph 
accommodated 15 days of recorded signs and symptoms and used pressure sensitive paper to 
simultaneously create a copy for the participant. Participants were asked to return completed 
graphs to the investigator using preaddressed stamped envelopes. To support treatment 
fidelity, all interventions were done by the principal investigator (C.J.), audiotaped, and audited 
for content by a research assistant. 
RESEARCH DESIGN AND METHODS 
A randomized control trial was used to pilot test the effect of a HF symptom training 
intervention on time to first event defined as death or a HF hospitalization. Participants 
diagnosed with chronic HF (n=105) were randomized to the HF SMART intervention or usual 
care. Six participants did not complete enrollment or died during their index admission, 
resulting in 99 individuals available for this analysis (Figure 2). All participants received weight 
scales and a HF self-care booklet published by the Heart Failure Society of America.46 
Participants randomized to the intervention group received one-on-one training on how to 
recognize and respond to symptoms. The primary hypothesis was that time to first event would 
be longer in HF patients who received the HF SMART intervention. The secondary hypothesis 
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was that improvements in HF self-care behaviors would be greater in patients who received the 
HF SMART intervention compared with those in the usual care arm. Human subjects’ approval 
was obtained from Stony Brook University and Stony Brook University Medical Center and all 
participants provided written informed consent. 
Sample  
Convenience sampling was used to enroll participants with a confirmed diagnosis of 
chronic HF. Criteria for study enrollment included English-speaking community dwelling adults 
making their own health care decisions and availability of a telephone for follow up interviews. 
Participants had to be cognitively intact as determined by a score of 24 or greater on the Mini-
Mental State Exam.47,48 Exclusion criteria included HF due to high output states (e.g. 
hyperthyroidism), major psychiatric illness, major uncorrected hearing impairment, planned 
discharge to a skilled nursing care facility, or terminal illness that would impede participation in 
a longitudinal trial. The rationale for these inclusion/exclusion criteria was the aim to include 
adults likely to engage in HF self-care.  
The sample was drawn from a New York suburban tertiary care hospital and 
surrounding community between February 2007 and January 2011. Eligible patients were 
identified during hospitalization, by referral from attending cardiologists and other community 
health care providers, or in response to study advertisements. The principal investigator or a 
research assistant approached patients who agreed to screening, described the study, obtained 
informed, written consent, and confirmed eligibility. Secondary contact information was 
collected at enrollment in anticipation of loss to follow-up due to change of address, death, or 
other difficulties with contacting participants. 
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Approximately 20% of patients in our prior studies had a high comorbidity score as 
measured by the Charlson Index.49 Therefore, to obtain a similar distribution, we balanced 
participants by comorbidity score (low, moderate, high) prior to randomization into the HF 
SMART program or usual care.  
Outcome Measures 
At enrollment, demographic, clinical, comorbidity data, overall perceived health and 
source of follow-up care (community/university health care provider or heart failure clinic) 
were collected on all participants by interview and chart review. In addition, all participants 
completed baseline measures of HF symptom awareness and self-care at baseline, which were 
repeated at 3-months. At 3 months, data were collected by telephone so participants were 
provided with a copy of the various scale answer choices to facilitate the process.  
Comorbidity was measured at enrollment using the interview format of the Charlson 
Index.49 Patients were queried about preexisting diseases (e.g., ulcer disease, diabetes). Most 
conditions are scored with 1 point although some (e.g., hemiplegia, cirrhosis) are assigned >1 
point. Scores can range from 0 to 34 but every study participant had a score >1 because all had 
HF. Responses were summed, weighted, and indexed into one of three categories (low, 
moderate, or high) according to the published method. Validity was demonstrated by the 
instrument authors when comorbidity category predicted mortality, complications, health care 
resource use, length of hospital stay, discharge disposition, cost.  
The HF Somatic Perception Scale (HFSPS v.3) is an 18-item 6-point Likert scale used to 
assess awareness and perceived distress of HF symptoms. The HFSPS asks how much the 
participant was bothered by 18 common HF symptoms during the last week and provides 6 
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response options ranging from 0 (not at all) to 5 (extremely). Scores range 0 to 90 with higher 
scores indicating higher perceived distress. The Cronbach’s coefficient alpha was .87 in this 
sample. 
Self-care was measured using the Self-Care of Heart Failure Index (SCHFI v.5), a 19-item 
scale capturing self-care maintenance, self-care management, and self-care confidence. Higher 
scores indicate better self-care. Discriminant and construct validity have been demonstrated 
previously.41 Cronbach’s alpha on the SCHFI maintenance, management, and confidence scales 
were 0.65, 0.45, and 0.75 in this sample, respectively.  
The primary outcome variable was defined as the composite end point of time to first 
event of HF hospitalization, emergency department admission for HF or HF-related cause and 
death. For example, a HF-related cause may be new onset atrial fibrillation or dehydration 
related to over diuresis. Events were tracked using the electronic hospital records of Stony 
Brook University Hospital. Subjects also were telephoned at 1- and 3-months and asked about 
all hospitalizations, emergent physician contacts and visits (i.e. telephone contact for symptom 
complaints), and admissions to outside hospitals. In addition, county death records were 
reviewed to ascertain vital status on any subject lost to follow-up. 
Data Analysis  
Standard descriptive statistics were used to describe subjects’ baseline 
sociodemographic, clinical characteristics and scale scores. Categorical variables were 
summarized by frequencies and proportions and continuous variables were summarized by the 
mean, median, standard deviation, and range. Chi square and student’s t tests were used to 
examine differences based on group assignment. Kaplan-Meier analysis was used to test the 
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hypothesis that time to first event would be longer in HF patients who received the HF SMART 
intervention. Time to first hospitalization for HF or death from any cause was calculated based 
on the time point when participants assumed self-care activities (e.g. discharge date). Results 
were coded to indicate whether or not a first event occurred within 90 days. As a 
complementary analysis, differences in discrete-time survival (any event within 90-day) were 
quantified using a chi square test. Finally, differences between groups in improvements to self-
care were quantified using t-tests without assuming equal variance; Hedges’ g were quantified 
as standardized indices of effect size. All analyses were conducted using IBM SPSS v.19.0.0 
(Chicago, IL). An intention-to-treat analysis was performed. 
Results 
The sample (n= 99) was predominately male, elderly, Caucasian, and married (Table 1). 
The majority of participants was educated at a high school level or had some college and most 
had an annual family income less than $40,000 per year. Few received care in a HF clinic or 
program. Most were taking an ACE inhibitor and a beta-blocker and had survived HF for 
approximately 5 years. Most were in NYHA class III or IV and had a low or moderate number of 
comorbid conditions. There were no significant differences between the intervention (n=48) 
and control (n=51) groups on any sociodemographic or clinical characteristic. There were no 
differences in self-care scores at baseline (Table 2).  
Of the 99 patients in the analysis, 27 were hospitalized for a HF-related event and four 
died within 90 days. The intervention group reported more events but number of events did 
not significantly differ between groups (usual care = 11 events (20%), intervention group = 16 
events (33.3%); χ2 (with Yates continuity correction) = 1.18, p=.26). The mean ± standard error 
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survival time was 76.2 ± 4.0 days in the usual care group. In the intervention group, the mean 
survival time was 76.7 ± 3.8 days. There was no difference in survival time between groups (Log 
Rank χ2 = 1.53, p=0.216) (Figure 3).  
Of the three SCHFI subscale scores, only self-care maintenance scores were acceptable 
(score of 70 or greater) at 90 days (Table 2). In paired t-tests, the intervention group had 
significantly improved self-care maintenance, management and confidence scores (all p<.01), 
and the usual care group had significantly improved self-care maintenance and management 
(both p<.01). Absolute and relative improvements in self-care maintenance were numerically 
superior in the intervention group compared with usual care (18.0 vs. 12.9 points; Hedges’ g = 
0.270), but the differences between groups were not statistically significant. Similarly, absolute 
and relative improvements in self-care confidence were numerically superior in the 
intervention group compared with usual care (10.2 vs. 4.8 points; Hedges’ g = 0.253); these 
differences were not statistically significant. In contrast, improvements in self-care 
management were numerically greater in the usual care group compared with the intervention 
group; this effect was small (Hedges’ g = -0.153) and insignificant (p=0.70).    
Discussion  
Targeting symptom recognition and response to improve self-care and decrease HF 
readmissions was the primary strategy used in this study. Prior to this study, no researchers 
have examined symptom awareness training for patients with HF. However, training to increase 
patient awareness of symptoms of diabetes and asthma has been reported.50, 51 The HF 
symptom awareness training tested in this study appeared to have an early benefit that was 
not sustained and resulted in no difference in event-free survival at 90 days. As the rate of 
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events was low in this sample, detecting a difference was not likely. Furthermore, we may have 
diluted the effect of the symptom training intervention by providing weight scales to all 
participants in this study. Koelling and colleagues reported more frequent weighing behavior 30 
days after a one-hour one-on-one HF discharge education protocol compared to usual care 
(66% vs 51%).30 Over half of all participants in the current study reported weighing themselves 
frequently or always at enrollment. At 90 days, daily weights increased to 93.1% in the 
intervention group and 77.1% in usual care. In addition to one other investigator, we have 
reported more consistent weight monitoring if the patient owned or was provided a scale.52, 53 
Another potential explanation for the increased number of events in the intervention 
group is use of a daily symptom graph. Eastwood and colleagues reported a similar outcome 
using a symptom diary. They provided a heart health diary to 124 patients and followed them 
for 6 months.54 Diary users had 47% more clinic visits than nonusers and 35% more telephone 
contacts. In this study, teaching patients to graph symptoms daily was intended to improve self-
care capacity by prompting appropriate attention and response to symptoms. Although not 
significantly different, there were more events in the intervention group. 
Baseline self-care scores were abysmal in both groups. Self-care maintenance, the first 
step in self-care, includes daily treatment adherence plus weight and symptom monitoring. 
Typically, HF patients are told which HF-related symptoms to monitor. The problem is they err 
in interpreting their symptoms using contexts derived from unrelated experiences (i.e. coughs 
due to a cold) or expectations (i.e. I am tired because I am old). We proposed that by providing 
both a physical and cognitive context for the interpretation of HF symptoms, patients would 
have the tools to improve their self-care resulting in fewer emergent hospitalizations for 
 13 
symptom management. Self-care management scores had a numerically larger improvement in 
the usual care group, which is counterintuitive and possibly due to measurement error. The 
internal consistency of self-care management also was poor in this sample further cautioning 
interpretation of these results. However, the larger improvement in self-care maintenance and 
confidence scores in the intervention group compared to usual care is promising. As a result, 
embedding meaningful symptom monitoring strategies in self-care maintenance interventions 
may be a realistic therapeutic target. Largely a consequence of significant improvements in self-
care in both groups, the effect sizes in this study were small; thus, a large number of 
participants are needed to show significant improvements in self-care and reductions in clinical 
events in future studies.  
The small sample size was a limitation. Enrollment was challenging partly due to 
competing studies, inconsistent referrals and reluctance to participating in a longitudinal study. 
The primarily Caucasian sample limits the generalizability of the results, but is reflective of the 
geographic area where the study was conducted. Other limitations included an inability to blind 
the individual collecting follow-up data by telephone. Participants were told not to tell the 
telephone interviewer to which group they were assigned. However, it was not uncommon for 
intervention participants to volunteer their status.  
Conclusions 
 HF disease management programs with an emphasis on self-care activities are reported 
to positively affect all-cause hospitalizations more than telephone contact or follow-up with a 
primary care physician.29 The HF SMART symptom training intervention was designed to be a 
brief, low cost, and feasible intervention in the context of the often time limited process 
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allotted to hospital discharge education. Increasing the dose of the intervention, particularly 
within the first 30 days post discharge may improve the duration of the effect. Lastly, 
determining the self-care capacity of patients also may assist in determining the appropriate 
dose of a symptom training intervention and follow up care. 
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Figure 1. HF SMART intervention* embedded in the Self-Care of Heart Failure model 
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Table 1. Description of the Sample (N=99). N and valid percent shown unless otherwise 
noted. 
Variable Total Sample 
(N=99) 
Intervention 
Group (n=48) 
Usual Care Group 
(n=51) 
Male gender 67 (67.7) 32 (66.7) 35 (68.6) 
Age (mean ± standard deviation 
[SD]) 
 
67.7 ± 12.1 
 
67.8 ± 12.7 
 
67.7 ± 11.6 
Race/ethnicity 
Caucasian  
African-American 
Hispanic 
Other 
 
88 (88.9) 
7 (7.1) 
3 (3.0) 
1 (1.0) 
 
43 (89.6) 
2 (4.2) 
2 (4.2) 
1 (2.1) 
 
45 (88.2) 
5 (9.8) 
1 (2.0) 
0 
Marital status 
Married 
Widowed 
Divorced, separated,   
never married 
 
57 (57.6) 
17 (17.2) 
25 (25.3) 
 
27 (56.3) 
7 (14.6) 
14 (29.2) 
 
30 (58.8) 
10 (19.6) 
11 (21.6) 
Living arrangements 
Lives alone 
Lives with others 
 
26 (26.3) 
73 (73.7) 
 
13 (27.1) 
35 (72.9) 
 
13 (25.5) 
38 (74.5) 
Highest level of education 
Less than 12 years 
High school diploma 
Some college/associate 
degree 
Baccalaureate degree 
Graduate degree 
 
16 (16.2) 
30 (30.3) 
28 (28.3) 
 
12 (12.1) 
13 (13.1) 
 
8 (16.7) 
11 (22.9) 
16 (33.3) 
 
6 (12.5) 
7 (14.6) 
 
8 (15.7) 
19 (37.3) 
12 (23.5) 
 
6 (11.8) 
6 (11.8) 
Total household income  
Less than $40,000/year 
$40,000-69,999/year 
$70,000 or more/year 
Don’t know or refused 
 
40 (40.4) 
27 (27.3) 
16 (16.2) 
16 (16.2) 
 
24 (50.0) 
9 (18.8) 
8 (16.7) 
7 (14.6) 
 
16 (31.4) 
18 (35.3) 
8 (15.7) 
9 (17.6) 
Overall perceived health 
Excellent or very good 
Good 
Fair 
Poor  
 
14 (14.1) 
24 (24.2) 
38 (38.4) 
23 (23.2) 
 
8 (16.7) 
11 (22.9) 
16 (33.3) 
13 (27.1) 
 
6 (11.8) 
13 (25.5) 
22 (43.1) 
10 (19.6) 
Attend a HF clinic ∞ 
Yes 
No 
 
28 (28.9) 
69 (71.1) 
 
15 (31.9) 
32 (68.1) 
 
13 (26) 
37 (74) 
Taking an ACE-inhibitor  55 (55.6) 26 (54.2) 29 (56.9) 
Taking an ARB 14 (14.1) 6  (12.5) 8 (15.7) 
Taking a beta blocker 86 (86.9) 43 (89.6) 43 (84.3) 
New York Heart Association 
(NYHA) functional class ∞ 
Class I or II 
Class III 
Class IV 
 
 
15 (15.2) 
47 (47.5) 
37 (37.4) 
 
 
5 (10.4) 
25 (52.1) 
18 (37.5) 
 
 
10 (19.6) 
22 (43.1) 
19 (37.3) 
Charlson Comorbidity Category    
Table
Mild 
Moderate 
Severe   
39 (39.4) 
44 (44.4) 
16 (16.2) 
19 (39.6) 
22 (45.8) 
7 (14.6) 
20 (39.2) 
22 (43.1) 
9 (17.6) 
HF type 
Systolic dysfunction 
Diastolic dysfunction 
Mixed HF 
Unknown 
 
35 (35.4) 
29 (29.3) 
29 (29.3) 
6 (6.1) 
 
16 (33.3) 
15 (31.3) 
13 (27.1) 
4 (8.3) 
 
19 (37.3) 
14 (27.5) 
16 (31.4) 
2 (3.9) 
Years with HF (mean ± SD) ∞ 5.5 ± 5.5 5.2 ± 5.3 5.9 ± 5.6 
HF Somatic Perception Scale 
score 
34.1 ± 18.1 34.7 ± 20.0 33.6 ± 16.5 
∞ missing data 
 
 
Figure 3. Kaplan Meier Survival Curve for days to event separated by treatment group. The 
lines cross which indicates a possible benefit at the beginning of the intervention, which lasted 
approximately 30-45 days. Overall, however, there was no difference in the hazard of events 
comparing the usual care and intervention groups. 
 
 
 
 
 
Figure
Table 2. Improvement in Self-care of HF scores between baseline and 90 days.  
 
Variable 
 
Intervention Group 
Mean (SD) 
Usual Care Group 
Mean (SD) 
 
t value (p) 
Self-Care 
Maintenance 
     
Baseline 
 
90 days 
 
Absolute Change 
 
Relative Change 
 
 
 
56.8 (22.0) 
 
76.9* (18.4) 
 
18.0 (20.8) † 
 
48.5% (72.4%) 
 
 
57.5 (24.0) 
 
70.8* (21.2) 
 
12.9 (17.1)† 
 
33.8% (47.4%) 
 
 
0.15 (.88) 
 
-1.2  (.24) 
 
1.07 (0.14) 
 
0.93 (0.18) 
Self-Care 
Management 
     
Baseline 
 
90 days 
 
Absolute Change 
 
Relative Change 
 
 
 
48.2 (19.3) 
 
60.4 (27.2) 
 
15.9 (27.9)† 
 
60.8% (96.2%) 
 
 
43.8 (21.1) 
 
61.1 (22.5) 
 
19.8 (22.8)† 
 
94.3% (151.1%) 
 
 
-1.0 (.30) 
 
.098 (.92) 
 
-0.54 (0.70) 
 
-0.94 (0.82) 
Self-Care Confidence 
     
Baseline 
 
90 days 
 
Absolute Change 
 
Relative Change 
 
 
 
54.3 (17.2) 
 
65.2 (19.1) 
 
10.2 (20.3)† 
 
29.2% (56.6%) 
 
 
54.4 (16.9) 
 
60.5 (20.7) 
 
4.8 (21.6) 
 
16.8% (44.2%) 
 
 
.02 (.98) 
 
-.93 (.36) 
 
1.03 (0.15) 
 
0.96 (0.17) 
* A score of 70 or higher is considered adequate. 
† Significant improvement (p<0.01) from baseline to 90 days by paired t-tests 
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 Heart failure (HF) is a significant health problem that affects nearly 6 million Americans.1 
Mortality and costs associated with HF are high. Among patients with HF, approximately half 
die within 5 years of diagnosis and costs are estimated to be over $30 billion annually.1,2 
Repetitive hospitalization for management of HF signs and symptoms is common and 
contributes to high costs associated with this syndrome.  
 HF is characterized by a variable illness trajectory and symptom profile.3-8 Consequently, 
determining prognosis is challenging for health care providers. Existing risk prediction models 
using objective clinical indicators are not always effective. Generalizability also may be limited 
based on populations used for testing the models and omission of the patient experience, 
particularly perception of symptoms and associated burden on activities of daily living.9,10 
Symptoms of HF drive care-seeking, healthcare utilization and predict quality of life and 
survival.11-14  Although symptoms of HF predict survival, discrepancies exist between patients' 
and health providers' perceptions of HF symptoms and associated burden.15-17 Accordingly, 
patient perception of symptoms, together with objective clinical indicators, is of potential value 
for prediction of both morbidity and mortality risk in this population.  
 The effect of HF symptom burden on survival has been investigated using measures that 
vary in method, number and type of symptoms assessed.6,13,14,17,18 Symptoms have been 
extrapolated from quality of life measures,18 measured with HF symptom instruments13,14 and 
study-specific questionnaires,17 and documented in symptom dairies.6 Timeframes for symptom 
reports range from daily assessment to a one month recall and the number of symptoms 
assessed range between four and eighteen.  
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 Variation in methods used to assess symptoms and associated burden may partially 
explain differences in findings related to symptoms and survival. Two studies of survival using 
four similar physical HF symptoms reported conflicting results.6,18 In a study using symptoms 
extrapolated from the Minnesota Living with HF questionnaire, an emotional symptom cluster 
predicted event-free survival, but the 4-item physical symptom cluster (shortness of breath, 
fatigue/increased need to rest, fatigue/low energy, difficulty sleeping) did not.18 Conversely, 
Moser and colleagues reported a four-fold increased risk of a clinical event using comparable 
physical symptoms. In the Moser study, a 30-day symptom diary was used to assess shortness 
of breath, swelling, fatigue, and difficulty sleeping.6 The widest array of symptoms was used in a 
third study of HF symptoms and survival.13 Survival was examined using version 3 of the HF 
Somatic Perception Scale (HFSPS), an 18-item physical HF symptom measure.19 HFSPS scores 
were combined with depression, anxiety and hostility scores. Moderate to severe symptom 
burden profiles were associated with increased risk of clinical events (HR 1.82 to 2.06) when 
controlling for demographic and clinical variables.13 Total scores of physical and psychological 
measures were used to delineate symptom profiles as mild, moderate or severe in nature.  
 There is substantial variation in how symptoms are experienced, reported by HF 
patients and documented by clinicians.6,8,20,21 Importantly, evidence suggests that patient 
report of symptoms and the associated burden is important in relation to health outcomes. In a 
retrospective analysis of 4537 HF patients, those reporting fewer numbers of symptoms had 
both higher hospital death rates and 30-day mortality.22 Furthermore, patients with fewer 
symptoms were less likely to receive effective cardiac medications compared with those 
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reporting multiple symptoms.  As the study was a retrospective chart review, it is not possible 
to determine whether symptoms were indeed absent, not reported or simply not documented.  
 The number and severity of HF symptoms may be useful and important predictors of 
clinical risk. Therefore, the purpose of this study was to quantify the validity and prognostic 
value of patient perception of a full range of HF symptoms using a HF-specific physical symptom 
measure. The internal consistency of the HF Somatic Perception Scale v.3 was examined and 
followed by examination of the prognostic value of the full 18 item scale and subscales to 
predict event-free survival over one year as a measure of validity. 
Method 
 A secondary analysis was conducted of 2 convenience samples with HF Somatic 
Perception Scale (HFSPS) data; one that assessed symptoms pre-randomization in a trial 
focused on symptom management12  and one that evaluated symptoms among community-
dwelling participants of two observational studies of heart failure symptoms.13,23 Sampling 
criteria was similar between the samples. Inclusion criteria included (a) a confirmed diagnosis 
of HF, (b) able to read and comprehend  fifth grade English, (c) reachable by telephone, (d) 
absence of major cognitive impairment, and (e) willing and able to provide informed consent. 
Exclusion criteria included (a) major uncorrected hearing impairment, (b) major psychiatric 
illness (e.g. schizophrenia), (c) major uncorrected visual impairment, (d) not expected to live for 
months, and (e) reversible HF (e.g. HF due to high output states). Human subjects approval was 
secured from each of the principal investigator's institutions. 
Measurement 
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 Physical HF symptoms were measured using the HFSPS, V.3, an 18-item Likert scale.19 
The HFSPS asks participants how much they are bothered by symptoms in the past week using 5 
response options ranging from 0 (I did not have the symptom) to 5 (extremely bothersome). 
Scores are summed with higher values indicating higher symptom burden. 
 Convergent validity provides evidence of validity by examining the correlation between 
different measures of a construct. To support convergent validity, correlation of theoretically-
related construct measures should be high.24,25 The Kansas City Cardiomyopathy Questionnaire 
(KCCQ) is a 23-item Likert scale health status measure that assesses physical function, 
symptoms, social function, self-efficacy, and quality of life among patients with HF.26 The KCCQ 
is a reliable and valid measure of health status responsive to change clinical status. The 6-item 
Physical Limitation subscale of the (KCCQ) was used to examine convergent validity. Scores 
range 1 to 36 on the Physical Limitation subscale. Higher scores indicate better function. The 
reliability of the Physical Limitation subscale is acceptable with a Cronbach's alpha of 0.90. We 
hypothesized that the correlation between the HFSPS and KCCQ Physical Limitation subscale 
would be significant. 
 Discriminant validity examines differentiation of constructs that are theoretically 
different. To support discriminant validity, correlation between two different constructs should 
be low.24,25 The Self-Care of HF Index (SCHFI) was used to quantify self-care.27 The SCHFI v.6.2 is 
a 22-item scale using a 4-point self-report response format to measure self-care maintenance 
(adherence behaviors), self-care management (response to symptoms) and self-care 
confidence. The 6-item Self-Care Management score was used to examine discriminant validity 
for this analysis because it reflects how quickly participants recognized and responded 
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symptoms as opposed to the physical experience of symptoms. Symptom recognition options 
ranged from 0 (I did not recognize it as a symptom of HF) to 4 (very quickly). Response to 
symptoms options included rating the likelihood of taking action to manage symptoms (e.g. 
taking an extra diuretic, reducing fluid intake) from 1 (not likely) to 4 (very likely). Scores are 
standardized to range from 0 to 100 with higher values indicated better symptom response 
behaviors. The Self-Care Management subscale of the SCHFI is multidimensional with a two 
factor structure representing symptom evaluation and treatment implementation. Therefore, a 
global reliability index is used to assess internal consistency. The global reliability index derived 
from the weighted least squares means and variance is  0.77 and 0.76 respectively.28 We 
hypothesized that the correlation between the HFSPS and SCHFI Self-Care Management 
subscale would be weak and insignificant. 
We completed a review of the electronic medical record at 1 year looking specifically for 
HF-related emergency room visits, hospitalizations or mortality. For the vast majority of events 
data were extracted directly from discharge summaries all participants received care locally and 
were part of an extensively-linked electronic medical record system. We also contacted study 
participants by phone to inquire about events that occurred outside of the health system 
network; we solicited sufficient detail directly from participants or their family members to 
determine whether or not the event was primarily related to their HF or for other reasons. All 
events underwent adjudication by two separate evaluators until 100% agreement was reached 
about the underlying reasons for emergent healthcare utilization.  
Analysis 
HFSPS item response means and standard deviations, and corrected inter-item 
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correlations were quantified. Item difficulty was assessed by quantifying the proportion of 
participants who provided the best possible response (I did not have this symptom). Item 
difficulty of 0.3 indicates that many (70%) participants had difficulty with the symptom, and 
item difficulty of 0.7 indicates that few (30%) participants had difficulty with the symptom; 
between 0.3 and 0.7 is the best range for item difficulty. Item discrimination was quantified by 
comparing item difficulty between participants with HFSPS total scores in the top and bottom 
thirds of the distribution. Confirmatory factor analysis was performed using Mplus v.6 (Los 
Angeles, California). Geomin (oblique) rotation was chosen for this analysis using weighted least 
square parameter estimation with mean- and variance-adjusted statistics. Results are 
presented in rotated factor loadings and standard errors. To assess model fit, overall model χ2 
tests, comparative fit indices (CFI), Tucker-Lewis indices (TLI), root mean square errors of 
approximation (RMSEA), standardized root mean square residuals (SRMSR), normed fit index 
(NFI), and adjusted goodness-of-fit index (AGFI) were calculated using common thresholds of 
acceptability.29 As the HFSPS was developed as a unidimensional scale, Cronbach’s alpha was 
calculated as an index of internal consistency. Pearson’s correlations were used to quantify 
convergent (KCCQ physical limitations score) and discriminant validity (SCHFI Self-Care 
Management). Finally, Cox proportional hazards modeling was performed using Stata MP v13 
(College Station, TX) to quantify 1-year HF event-risk (emergency room visit or hospitalization 
for HF or all-cause death) as a function of the HFSPS scores. The proportional hazards 
assumption was justified based on Schoenfeld residuals. Hazard ratios (HR) and 95% confidence 
intervals (CI) are presented. To account for the influence of many other factors, the influence of 
symptom profiles on event-free survival was adjusted for the Seattle HF Score. The Seattle HF 
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Score was calculated based on the original model developed by Levy and colleagues.10 In brief, 
demographic (i.e. age, gender) objective clinical indices (i.e. ischemic etiology, NYHA functional 
class, left ventricular ejection fraction, systolic blood pressure, hemoglobin, % lymphocyte 
count, uric acid, sodium, cholesterol) and HF treatment (i.e. beta blocker, angiotensin 
converting enzyme inhibitor, allopurinol, diuretic dose, statin use, and device therapy) were 
multiplied by respective slope coefficients10 to generate a single composite risk-prediction score 
that in this sample ranged from -0.16 to 3.34.  
Results 
 The samples used in this psychometric analysis are presented in Table 1. In brief, the 
sample was predominantly male (63.2%), Caucasian (85.2%) older adults (mean age = 62.6±12.8 
years). A majority of participants (67.2%) had NYHA class III/IV symptoms.   
Average inter-item correlations on the HFSPS ranged from 0.32 (It was hard for me to 
breath) to 0.35 (I had a cough) (Table 2). Item difficulty ranged from 0.09 (I was tired – the most 
commonly experienced symptom) to 0.66 (paroxysmal nocturnal dyspnea – the least commonly 
experienced symptom). Most items were discriminatory regarding the top and bottom 33.3% of 
physical HF symptom burden. In contrast, having a cough, being tired, and waking up at night to 
urinate were not helpful in discriminating between participants who reported least versus most 
burdensome physical HF symptoms because they were either highly-prevalent or because they 
were relatively normally distributed across response options. 
The confirmatory factor analysis of the HFSPS is presented in Table 3. Several fit indices 
reached and others were close to reaching thresholds of acceptability; thus, the fit of the HFSPS 
as a single scale could be improved. The best fit exploratory factor analysis of the HFSPS is also 
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presented in Table 3. The resulting subscales were labeled according to dominant features as 
“dyspnea,” “chest discomfort,” “early and subtle” and “edema.” Considering these four factors, 
the fit of the HFSPS was improved considerably.    
Cronbach's alpha of the 18-item HFSPS was 0.90. Single item deletion did not result in 
significant improvement of internal consistency. Cronbach's alpha was 0.89 on the 6-item 
dyspnea subscale. Cronbach’s alpha was 0.75 on the 7-item "early and subtle" subscale as well 
as the edema subscale. The chest discomfort subscale had a Cronbach's alpha of 0.68.  
Convergent validity testing of the HFSPS with the KCCQ Physical Limitations score, and 
discriminant validity testing of the HFSPS with the SCHFI Self-Care Management are presented 
in Table 4. There were strong correlations between both the HFSPS and subscales and the KCCQ 
Physical Limitations score indicating similarity between measures of theoretically-related 
constructs. The HFSPS and subscales were not correlated with SCHFI Self-Care Management 
score confirming discriminant validity. Convergent and discriminant validity testing was limited 
to the total HFSPS and subscales for "dyspnea" and "early and subtle" subscales as the "chest 
discomfort" and "edema" subscales had few items. 
The results of predictive validity testing are presented in Table 5. The 18-item HFSPS, 6-
item dyspnea subscale, and 7-item early and subtle subscale were significantly associated with 
1-year event-risk when controlling for the Seattle HF Score. Survival curves depicting event-free 
survival differences across a gradient of physical symptoms by HFSPS tertiles are presented in 
Figure 1. The severe symptom tertile is associated with markedly increased risk of HF-related 
clinical risks compared with the low symptom tertile on the 18-item HFSPS (HR=1.65, p=0.048), 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
6-item dyspnea subscale (HR=1.70, p=0.029) and 7-item early and subtle subscale (HR=1.99, 
p=0.010). 
Discussion 
 The HFSPS is a valid and reliable measure of symptoms in HF in this sample of 378 adults 
with symptomatic HF. The HFSPS total, "dyspnea" and "early and subtle" subscale scores 
predicted HF event-free survival independent of a commonly used prognostication model.10 
Thus, the analysis indicates that patient perception of the physical symptoms of HF adds value 
when predicting clinical events.  
 The "dyspnea subscale" is a robust subscale with good reliability and validity that 
examines a full range and severity of dyspnea symptoms related to HF. We found that the 
dyspnea subscale was effective in predicting HF-related clinical events. Clinical events were 
adjudicated for HF specific events in this study. Conversely, dyspnea did not predict HF-related 
hospitalizations in the study by Ekman.17 However, only two dyspnea symptoms were assessed 
and one (orthopnea) was assessed as present or absent. Similarly, dyspnea did not predict 
cardiac events in the study by K. Lee and colleagues.18 A potential explanation of is that 
dyspnea was limited to one item and clustered with fatigue and sleep disturbance in the 
survival analysis. The flexibility of using the HFSPS dyspnea subscale is of interest for clinical and 
research use. 
 Assessment of the early and subtle symptoms of HF has clinical value. We found that 
increased severity of the early and subtle HF symptoms is associated with almost two times the 
risk of a clinical event within one year. Fatigue as a singular symptom (RR=1.09, p=0.018)17 or 
clustered with other early and subtle symptoms (HR=1.00, p=0.011)14 was a significant 
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predictor of HF event risk in other studies. Accordingly, there are important implications of this 
finding for both patients and health care providers. First, patients often have difficulty 
recognizing and responding to escalation in burden of the subtle nonspecific symptoms of 
HF.20,30 Lack of attention to early and subtle signs of decompensation may contribute to delay in 
self-management and or care-seeking.20 Patients with HF are typically instructed to monitor 
daily weights as an objective measure of increasing congestion. However, a disassociation 
between weight and dyspnea has been reported potentially increasing the importance of 
assessing additional symptom parameters.31-33 Second, among patients with HF, cognitive 
impairment is common, can be subtle, and potentially impedes symptom reporting.34-36 Despite 
the prevalence of cognitive impairment in this population, it is infrequently documented in the 
medical record by health care providers.37 Educating patients regarding the importance of 
monitoring the early and subtle symptoms of HF that are commonly attributed to less 
threatening illness is warranted. Involving family and significant others in the education may 
improve effectiveness in detecting insidious increases in symptom severity. Taken together, 
evidence suggests that assessment of a full range of HF symptoms may be useful in evaluating 
therapeutic outcomes, predicting survival, and informing clinical decision making.  
Strengths and Limitations 
 There are several strengths and limitations to be considered in interpreting these 
results. Strengths of this analysis lie in use of a HF-specific symptom scale and prospective 
documentation of symptom burden. Use of the HFSPS also afforded assessment of a full range 
of symptoms including those potentially not reported by patients unless specifically asked. The 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
survival analysis was strengthened by adjusting for clinical and treatment variables known to 
influence survival.  
 Limitations include a primarily male Caucasian sample limiting generalizability of the 
findings. In addition, the fit indices in this analysis were not perfect, but very good by most 
metrics. Although survival analyses are robust with smaller samples, additional testing of the 
predictive validity of the HFSPS and subscales is needed. Future testing also is needed to 
examine differential item functioning by gender, race, ethnicity and other factors. 
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What's New and Important? 
 
 Patient perception of HF symptoms is an effective predictor of 1-year survival 
 The HFSPS Dyspnea subscale can be used alone to predict 1-year survival. It has validity 
and strong internal consistency. 
 Early and subtle symptoms of HF also have value in predicting 1-year survival. 
 
 
What is New (bulleted list of 2-3 highlights from article)
 
 
Abbreviations: ACE-I = Angiotensin Converting Enzyme-Inhibitor, ARB = Angiotensin Receptor Blocker, 
BUN = blood urea nitrogen, IQR = interquartile range, NYHA = New York Heart Association, SD = 
standard deviation. 
 
Table 1: Characteristics of the sample (n=378)  
 Sample 1 (n=105) Sample 2 (n=273) Full Sample (n=378) 
Patient Characteristics: 
mean±SD, n (%), 
median [IQR] 
mean±SD, n (%), 
median [IQR] 
mean±SD, n (%), 
median [IQR] 
Age (years) 67.9±12.3 57.3±13.2 62.6±12.8 
Female 33 (31.4%) 106 (38.8%) 139 (36.8%) 
Non-Hispanic Caucasian 93 (88.6%) 229 (83.9%) 322 (85.2%) 
Married/Living with Partner 62 (59.1%) 173 (63.4%) 235 (62.2%) 
Charlson Comorbidity Index (weighted) 3.1±1.5 2.3±1.4 2.5±1.3 
General Heart Failure Characteristics:    
Time with heart failure in months:  48 [12-102] 49 [16-96] 49 [14-98] 
NYHA Functional Class:    
Class I/II 17 (16.3%) 106 (38.8%) 123 (32.5%) 
Class III 48 (46.2%) 157 (57.64%) 205 (54.2%) 
Class IV 39 (37.5%) 10 (3.7%) 49 (13.0%) 
Left ventricular ejection fraction (%) 37.5±16.8 28.3±12.4 32.8±14.0 
Prescribed a β-blocker 91 (86.7%) 248 (90.8%) 339 (89.7%) 
Prescribed an ACE-I or ARB 64 (61%) 223 (81.7%) 287 (75.9%) 
Serum sodium (mEq/L) 138.9±3.8 137.8±3.3 138.3±3.4 
Serum BUN-to-creatinine ratio 
(mg/dL:1) 
23.6±8.8 20.2±9.5 21.8±9.1 
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Table 2:  Item Responses, Inter-item Correlation and Discrimination for the Heart Failure Somatic Perception Scale (n=378) 
 
Item  
I did not 
have this 
symptom 
Not at all  →  Extremely 
Mean 
± SD 
Inter-item 
correlation 
Discrimination 
1. I could feel my heart beat get faster 50.1% 14.2% 16.7% 9.3% 6.3% 3.3% 1.17±1.45 0.345 0.413 
2. I could not breathe if I lay down flat 51.3% 5.2% 14.5% 8.7% 13.7% 6.6% 1.48±1.75 0.330 0.718 
3. I felt discomfort or pain in my chest 51.2% 10.1% 16.7% 11.5% 7.9% 2.5% 1.22±1.49 0.344 0.447 
4. I had an upset stomach 55.7% 6.8% 18.3% 10.3% 5.7% 3.0% 1.13±1.46 0.346 0.437 
5. I had a cough  40.8% 15.1% 20.8% 11.2% 6.6% 5.5% 1.44±1.53 0.353 0.259 
6. I was tired  9.1% 8.5% 25.5% 17.9% 23.4% 15.7% 2.85±1.50 0.331 0.203 
7. I could not catch my breath  39.7% 5.8% 18.9% 14.5% 12.1% 9.0% 1.81±1.75 0.324 0.787 
8. My feet were swollen at the end of the day  47.0% 14.2% 11.7% 11.2% 6.8% 9.0% 1.44±1.71 0.339 0.473 
9. I woke up at night because I could not breathe  66.0% 6.6% 9.6% 5.5% 7.4% 4.9% 0.96±1.56 0.335 0.633 
10. My shoes were tighter than usual… 59.7% 9.0% 10.7% 9.0% 6.0% 5.5% 1.09±1.58 0.340 0.505 
11. I gained weight in the past week  56.5% 10.7% 12.9% 9.4% 6.6% 3.8% 1.10±1.51 0.347 0.399 
12. I could not do my usual activities because of SOB 32.0% 10.9% 17.5% 15.3% 14.2% 10.1% 1.99±1.74 0.325 0.694 
13. Getting dressed made it hard to breathe 51.0% 11.5% 15.6% 8.8% 8.8% 4.4% 1.26±1.56 0.326 0.751 
14. My clothes felt tighter around my waist  59.3% 11.7% 11.2% 7.1% 6.3% 4.4% 1.02±1.50 0.336 0.533 
15. I woke up at night because I had to urinate  16.7% 25.4% 23.0% 16.4% 11.5% 7.1% 2.02±1.48 0.350 0.200 
16. I had to rest more than usual during the day  23.9% 10.7% 25.8% 16.2% 14.8% 8.5% 2.13±1.60 0.330 0.499 
17. It was hard for me to breathe  41.3% 10.1% 15.0% 12.3% 12.6% 8.7% 1.71±1.76 0.323 0.859 
18. I did not feel like eating  53.8% 14.8% 13.9% 9.8% 4.1% 3.6% 1.06±1.42 0.345 0.485 
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Table 3: Confirmatory and Exploratory Factor Analysis for the 18-Item Heart Failure Somatic Perception Scale (n=378) 
 
 
HFSPS 
Dyspnea Chest 
Discomfort               
Early 
Subtle 
Edema 
1. I could feel my heart beat get faster 0.51±0.04  0.78±0.05   
2. I could not breathe if I lay down flat 0.77±0.02 0.69±0.05    
3. I felt discomfort or pain in my chest 0.53±0.04  0.68±0.07   
4. I had an upset stomach 0.49±0.05   0.43±0.07  
5. I had a cough  0.38±0.04   0.35±0.09  
6. I was tired  0.71±0.03   0.72±0.06  
7. I could not catch my breath  0.89±0.01 0.78±0.07    
8. My feet were swollen at the end of the day  0.71±0.03    0.77±0.06 
9. I woke up at night because I could not breathe  0.76±0.03 0.72±0.06    
10. My shoes were tighter than usual at the end of the day  0.74±0.03    0.78±0.06 
11. I gained weight in the past week  0.50±0.04    0.52±0.06 
12. I could not do my usual activities because I was short of breath  0.83±0.02 0.59±0.09    
13. Getting dressed made it hard to breathe 0.81±0.02 0.58±0.07    
14. My clothes felt tighter around my waist  0.66±0.04   0.53±0.06  
15. I woke up at night because I had to urinate  0.38±0.04   0.27±0.07  
16. I had to rest more than usual during the day  0.73±0.03   0.76±0.06  
17. It was hard for me to breathe  0.92±0.01 0.79±0.08    
18. I did not feel like eating  0.50±0.04   0.48±0.08  
Goodness of Fit   
358 (87) 
<0.001 
0.091 
0.046 
0.969 
0.960 
0.945 
0.929 
χ
2
 (df) 1176 (135) 
p-value <0.001 
RMSEA‡ 0.143 
SRMR 0.100 
CFI 0.880 
NFI 0.867 
TLI 0.864 
AGFI 0.849 
 
Abbreviations: AGFI = Adjusted Goodness-of-fit Index; CFI = Comparative Fit Index; df = degrees of freedom; NFI = Normed Fit Index; RMSEA = root 
mean square error of approximation; SRMR = standardized root mean square residuals; TLI = Tucker-Lewis Index. 
Thresholds for Acceptable Fit 
AGFI ≥ 0.85 
CFI and TLI ≥ 0.95 
NFI ≥ 0.90 
RMSEA = 0.05-0.08 
SRMR <1.0 
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Table 4: Convergent and Discriminant Validity for the Heart Failure Somatic Perception 
Scale  
Linear correlations 
KCCQ 
Physical Limitations 
SCHFI Self-Care 
Management 
HFSPS -0.544† 0.181 
HFSPS dysnea -0.529† 0.182 
HFSPS early -0.390† 0.106 
† p<0.0001 for all correlations with Bonferroni correction for multiple measures   
Abbreviations: HFSPS = Heart Failure Somatic Perception Scale; KCCQ = Kansas City Cardiomyopathy 
Questionnaire; SCHFI = Self-Care of Heart Failure Index (v6).  
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Table 5: Predictive Validity for the Heart Failure Somatic Perception Scale  
365-day Adjusted Hazard Ratio† 95%CI p-value 
HFSPS 1.012 1.001-1.024 0.038 
HFSPS dyspnea 1.031 1.003-1.060 0.031 
HFSPS early 1.030 1.003-1.058 0.028 
† adjusted for the Seattle Heart Failure Score 
Abbreviations: HFSPS = Heart Failure Somatic Perception Scale 
Table
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 
0
.0
0
0
.2
5
0
.5
0
0
.7
5
1
.0
0
0 100 200 300 400
time in days
Tertile 1 (Low) Tertile 2 (Moderate)
Tertile 3 (Severe)
Survivor functions
adjusted for SEATTLE
≈
HR = 1.22 (0.73-2.04), p=0.458
HR = 1.65 (1.01-2.71), p=0.047
Heart Failure Event-Free Survival by HFSPS Score Tertiles
Adjusted for th  Seattle Heart Failure Score
0
.0
0
0
.2
5
0
.5
0
0
.7
5
1
.0
0
0 100 200 300 400
time in days
Tertile 1 (Low) Tertile 2 (Moderate)
Tertile 3 (Severe)
Survivor functions
adjusted for SEATTLE
≈
HR = 0.89 (0.52-1.53), p=0.679
HR = 1.70 (1.06-2.75), p=0.029
Heart Failure Event-Free Survival by HFSPS Dyspnea Tertiles
Adjusted for the Seattle Heart Failure Score
0
.0
0
0
.2
5
0
.5
0
0
.7
5
1
.0
0
0 100 200 300 400
time in days
Tertile 1 (Low) Tertile 2 (Moderate)
Tertile 3 (Severe)
Event-Free Survival
adjusted for the Seattle Heart Failure Score
≈
HR = 1.93 (1.14-3.28), p=0.015
HR = 1.99 (1.18-3.34), p=0.010
Heart Failure Event-Free Survival by HFSPS Early Symptom Tertiles
Adjusted for the Seattle Heart ilure Score
A
B
C
Figure
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
KEY WORDS: heart failure; symptoms; survival; factor analysis, statistical 
 
Key words-Keywords must be compatible with MeSH headings in Medline
